

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Health Technology Appraisal

Relugolix with oestradiol and norethindrone acetate for heavy menstrual bleeding associated with uterine fibroids ID3842

Provisional stakeholder list

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> • Gedeon Richter (relugolix) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Bladder and Bowel Community • British Fibroid Trust • Fibroid Network • Hysterectomy Association • South Asian Health Foundation • Specialised Healthcare Alliance • Wellbeing of Women • Women's Health Concern <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Royal College of General Practitioners • Royal College of Nursing • Royal College of Obstetricians and Gynaecologists • Royal College of Pathologists • Royal College of Physicians • Royal Pharmaceutical Society • Royal Society of Medicine • UK Clinical Pharmacy Association <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health and Social Care • NHS Aylesbury CCG • NHS Coastal West Sussex CCG • NHS England • Welsh Government 	<p><u>General</u></p> <ul style="list-style-type: none"> • All Wales Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Confederation • Scottish Medicines Consortium • Welsh Health Specialised Services Committee <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> • Accord Healthcare (aspirin, ibuprofen, naproxen, tranexamic acid) • Advanz Pharma (tranexamic acid) • Alliance Pharmaceuticals (aspirin) • Aspire Pharma (ibuprofen) • AstraZeneca (goserelin, naproxen) • Aurobindo Pharma (ibuprofen, naproxen) • Bayer (combined hormonal contraception, levonorgestrel) • Besins Healthcare (utrogestan) • The Boots Company (aspirin, ibuprofen, naproxen)

Provisional stakeholder list for the health technology appraisal of relugolix with oestradiol and norethindrone acetate for heavy menstrual bleeding associated with uterine fibroids ID3842
Issue date: November 2020

Consultees	Commentators (no right to submit or appeal)
	<ul style="list-style-type: none"> • Bowmed Ibisqus (tranexamic acid) • Consilient Health (combined hormonal contraception) • Dexcel Pharma (aspirin) • Dr Reddy's Laboratories (aspirin) • Flamingo Pharma (ibuprofen) • Focus Pharmaceuticals (tranexamic acid) • Gedeon Richter (levonorgestrel) • GlaxoSmithKline (aspirin) • Healthcare Pharma (aspirin) • Infirst (ibuprofen) • Intraparm Laboratories (aspirin) • Ipsen (decapeptyl) • M&A Pharmachem (aspirin) • Martindale Pharma (aspirin) • McNeil Products (ibuprofen) • Merck Sharp & Dohme (combined hormonal contraception) • Mercus Labs (oestradiol) • Morningside Healthcare (combined hormonal contraception) • Mylan (ibuprofen, oestradiol, tranexamic acid) • Novartis (oestradiol) • Omega Pharma (ibuprofen) • Orion Pharma (oestradiol, naproxen) • Pfizer (aspirin, combined hormonal contraception, ibuprofen, oestradiol, tranexamic acid) • Pinewood Healthcare (aspirin, ibuprofen) • Reckitt Benckiser Healthcare (ibuprofen) • Rivopharm (tranexamic acid) • Sigma Pharmaceuticals (tranexamic acid) • Stirling Anglian Pharmaceuticals (naproxen) • Stragen UK (tranexamic acid) • Takeda (leuprorelin) • Theramax UK (combined hormonal contraception, oestradiol) • Typharm (leuprorelin)

Consultees	Commentators (no right to submit or appeal)
	<ul style="list-style-type: none"> • Wockhardt UK (ibuprofen, naproxen) • Zentiva (aspirin, tranexamic acid) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Campbell Collaboration Social Welfare Group • Cochrane Menstrual Disorders and Subfertility Group • Genomics England • MRC Clinical Trials Unit • National Institute for Health Research <p><u>Associated Public Health groups</u></p> <ul style="list-style-type: none"> • Public Health England • Public Health Wales

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Document (FAD).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Document (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations

¹ Non-company consultees are invited to submit statements relevant to the group they are representing.

and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical specialists or patient experts.